Citations

Clear

186 citation(s) found for "Frantz, R".

Identifying histopathologic features of erythema elevatum diutinum and granuloma faciale
Chukwuma, Olivia, Satcher, Kerrie G. , Kallis, Penelope , Vincek, Vladimir , Sokumbi, Olayemi , Satcher, Kerrie , Kallis, Penelope J , Motaparthi, Kiran , Frantz, Robert P.

Mayo Clinic

Journal of Cutaneous Pathology | December 23, 2021 | Volume: 49 | Issue: 3 | Pages: 323-326

10.1111/cup.14191 | PMID 34939211 Get It

Transcatheter Nonductal Reverse Potts Shunt Creation in Pulmonary Arterial Hypertension
Anderson, Jason H. , Frantz, Robert P. , Cajigas, Héctor , Cabalka, Allison K. , Frantz, Robert P , Cajigas, Hector R , Taggart, Nathaniel W , Anderson, Jason , Taggart, Nathaniel W.

Mayo Clinic

Circulation: Cardiovascular Interventions | December 21, 2021 | Volume: 15 | Issue: 1 | Pages: No page available

10.1161/circinterventions.121.011315 | PMID 34930014 Get It

Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
Vizza, Carmine Dario , Benza, Raymond L. , White, R. James , Adir, Yochai , Andreassen, Arne K., Balasubramanian, Vijay , Bartolome, Sonja, Carlsen, Jørn , Camacho, Rafael Enrique Conde, Ford, H. James , Humbert, Marc , Naeije, Robert , Orfanos, Stylianos E. , Oudiz, Ronald J. , Perrone, Sergio V. , Shlobin, Oksana A. , Torres, Fernando , Vachiéry, Jean Luc, Wang, Kuo‐Yang , Liu, Yan , Golden, Gil, Matsubara, Hiromi , Benza, Raymond L. , Oudiz, Ronald , Lang, Iréne , Badagliacca, Roberto , Rosenkranz, Stephan , Andreassen, Arne K., Blanco, Isabel , Bourge, Robert C. , Camacho, Rafael Enrique Conde , D’Alto, Michele , Farber, Harrison W. , Frantz, Robert P. , Ghio, Stefano , Gomberg‐Maitland, Mardi , Simon, Marc A. , Sitbon, Olivier , Vachiéry, Jean‐Luc , Yacoub, Magdi Habib

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | December 14, 2021 | Volume: 205 | Issue: 7 | Pages: 751-760

10.1164/rccm.202109-2079pp | PMID 34905704 Get It

Abstract Despite numerous therapeutic advances in pulmonary arterial hypertension, patients continue to suffer high morbidity and mortality, particularly considering a median age of 50 years. This article explores whether early, robust reduction of right ventricular afterload would facilitate substantial improvement in right ventricular function and thus whether afterload reduction should be a treatment goal for pulmonary arterial hypertension. The earliest clinical studies of prostanoid treatment in pulmonary arterial hypertension demonstrated an important link between lowering mean pulmonary arterial pressure (or pulmonary vascular resistance) and improved survival. Subsequent studies of oral monotherapy or sequential combination therapy demonstrated smaller reductions in mean pulmonary arterial pressure and pulmonary vascular resistance. More recently, retrospective reports of initial aggressive prostanoid treatment or initial combination oral and parenteral therapy have shown marked afterload reduction along with significant improvements in right ventricular function. Some data suggest that reaching threshold levels for pressure or resistance (components of right ventricular afterload) may be key to interrupting the self-perpetuating injury of pulmonary vascular disease in pulmonary arterial hypertension and could translate into improved long-term clinical outcomes. Based on these clues, the authors postulate that improved clinical outcomes might be achieved by targeting significant afterload reduction with initial oral combination therapy and early parenteral prostanoids.
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
Benza, Raymond L. , Channick, Richard N. , Chin, Kelly , McLaughlin, Vallerie V. , Zamanian, Roham T. , Cravets, Matt , Bruey, Jean‐Marie, Roscigno, R.F., Mottola, David, Elman, Erin, Zisman, Lawrence S. , Ghofrani, Hossein‐Ardeschir, Chin, Kelly M , Benza, Raymond L. , Frantz, Robert P. , Channick, Richard N. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier , Hemnes, Anna R. , Ghofrani, Hossein‐Ardeschir

Mayo Clinic

Pulmonary Circulation | October 22, 2021 | Volume: 11 | Issue: 4 | Pages: 1-7

10.1177/20458940211057071 | PMID 34790348 Get It

Aberrant kinase signaling that involves platelet‐derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c‐KIT) pathways may be responsible for vascular remodeling in pulmonary arterial hypertension. Targeting these specific pathways may potentially reverse the pathological inflammation, cellular proliferation, and fibrosis associated with pulmonary arterial hypertension progression. Seralutinib (formerly known as GB002) is a novel, potent, clinical stage inhibitor of PDGFRα/β, CSF1R, and c‐KIT delivered via inhalation that is being developed for patients with pulmonary arterial hypertension. Here, we report on an ongoing Phase 2 randomized, double‐blind, placebo‐controlled trial (NCT04456998) evaluating the efficacy and safety of seralutinib in subjects with World Health Organization Group 1 Pulmonary Hypertension who are classified as Functional Class II or III. A total of 80 subjects will be enrolled and randomized to receive either study drug or placebo for 24 weeks followed by an optional 72‐week open‐label extension study. The primary endpoint is the change from baseline to Week 24 in pulmonary vascular resistance by right heart catheterization. The secondary endpoint is the change in distance from baseline to Week 24 achieved in the 6‐min walk test. A computerized tomography sub‐study will examine the effect of seralutinib on pulmonary vascular remodelling. A separate heart rate monitoring sub‐study will examine the effect of seralutinib on cardiac effort during the 6‐min walk test.
Health‐related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR)
Minhas, Jasleen , Narasimmal, S.P., Bull, Todd M., Marco, Teresa De , McConnell, John W., Lammi, Matthew R. , Thenappan, Thenappan , Feldman, Jeremy P., Sager, Jeffrey S., Badesch, David B., Ryan, John , Grinnan, Daniel, Zwicke, Dianne, Elwing, Jean , Moss, John E. , Eggert, Michael, Shlobin, Oksana A. , Bartolome, Sonja, Mathai, Stephen C. , Mazimba, Sula , Pugliese, Steven C. , Al‐Naamani, Nadine , investigators, PHAR, P Frantz, Robert, Thenappan, Thenappan , Minhas, Jasleen , Al-Naamani, Nadine , Mathai, Stephen C , Grinnan, D. , Horn, Evelyn M. , Frantz, Robert P. , investigators, PHAR

Mayo Clinic

Pulmonary Circulation | October 1, 2021 | Volume: 11 | Issue: 4 | Pages: 1-11

10.1177/20458940211053196 | PMID 34671455 Get It

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, morbid, potentially curable subtype of pulmonary hypertension that negatively impacts health‐related quality of life (HRQoL). Little is known about differences in HRQoL and hospitalization between CTEPH patients and idiopathic pulmonary arterial hypertension (IPAH) patients. Using multivariable linear regression and mixed effects models, we examined differences in HRQoL assessed by emPHasis‐10 (E10) and SF‐12 between CTEPH and IPAH patients in the Pulmonary Hypertension Association Registry, a prospective multicenter cohort of patients newly evaluated at a Pulmonary Hypertension Care Center. Multivariable negative binomial regression models were used to estimate incidence rate ratios (IRR) for hospitalization amongst the two groups. We included 461 IPAH patients and 169 CTEPH patients. Twenty‐one percent of CTEPH patients underwent pulmonary thromboendarterectomy (PTE) before the end of follow‐up. At baseline, patients with CTEPH had significantly worse HRQoL (higher E10 scores) (ß 2.83, SE 1.11, p = 0.01); however, differences did not persist over time. CTEPH patients had higher rates of hospitalization (excluding the hospitalization for PTE) compared to IPAH patients after adjusting for age, sex, body mass index, WHO functional class and six‐minute walk distance (IRR 1.66, 95%CI 1.04–2.65, p = 0.03). CTEPH patients who underwent PTE had improved HRQoL as compared to those who were medically managed, but patients who underwent PTE were younger, had higher cardiac outputs and greater six‐minute walk distances. In this large, prospective, multicenter cohort, CTEPH patients had significantly worse baseline HRQoL and higher rates of hospitalizations than those with IPAH. CTEPH patients who underwent PTE had significant improvements in HRQoL.
Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
Morland, Kellie , Raina, Amresh, Nails, Abigail, Classi, Peter, Etschmaier, Martine, Frantz, Robert P.

Mayo Clinic

Pulmonary Circulation | September 3, 2021 | Volume: 11 | Issue: 4 | Pages: 1-7

10.1177/20458940211046761 | PMID 35024138 Get It

While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment. This study aimed to understand, directly from patients with pulmonary arterial hypertension, why pPCY was refused and, in some cases, later accepted. Interviews were conducted with 25 pulmonary arterial hypertension patients who previously refused pPCY therapy (Group A: Refused/Never initiated (n = 9) and Group B: Refused/Initiated (n = 16)). Patients in both groups believed that pPCY could improve their symptoms, slow disease progression, and provide them a greater ability to perform activities. Reasons for refusal included concern over side effects and the perceived limitations of pPCY on daily activities. Group A perceived their decision as a balance between quality of life and prolonging life and most acknowledged they would reconsider pPCY if other treatment options were exhausted. Group B cited they initiated therapy due to a worsening of symptoms, disease progression, to improve quality of life, to be there for their family, or a desire to live. Following initiation, Group B indicated their experience met expectations with reduced symptoms, slowed disease progression, and perception of improved survival; concerns related to pPCY were described as manageable. Given the efficacy of pPCY therapy, clinicians should apply knowledge of these findings in clinical practice. Patients noted improvements to parenteral pump technologies to include smaller size, water resistance, and implantability may increase their acceptance of this modality. Development efforts should focus on technologies that increase the acceptance of pPCY when indicated.
Mate‐pair sequencing identifies a cryptic BMPR2 mutation in hereditary pulmonary arterial hypertension
Chalmers, Sarah , Thompson, Laura L. , Hoppman, Nicole L., Smadbeck, James B. , Balcom, Jessica R. , Harris, Faye R. , Vasmatzis, George , Wylam, Mark E. , Chalmers, Sarah J, E Wylam, Mark , Murphy, Stephen J. , Thompson, Laura L., Frantz, Robert P.

Mayo Clinic

Pulmonary Circulation | July 12, 2021 | Volume: 10 | Issue: 3 | Pages: 1-4

10.1177/2045894020933081 | PMID 34290857 Get It

Current guidelines suggest screening all patients with idiopathic pulmonary arterial hypertension for genetic aberrations, particularly mutations in Bone Morphogenic Protein Receptor Type II (BMPR2), the gene most commonly implicated in the pathogenesis of PAH. Herein, we present a novel technique used to identify a pathogenic germline BMPR2 alteration in a 36‐year‐old female and family members with hereditary pulmonary arterial hypertension who each screened negative by standard cytogenetics and molecular genetics testing.
The effects of sildenafil and acetazolamide on breathing efficiency during hypoxic exercise
Snyder, Eric M., Olson, Thomas P. , Hulsebus, Minelle L., Orban, Marek , Johnson, Bruce D., Lalande, Sophie , Somers, Virend K. , Frantz, Robert P.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.1173.13 Get It

The ability to work efficiently at altitude is impaired by the reduced arterial oxygen tension. Acetazolamide may improve systemic saturation (SaO 2 ) by stimulating ventilation but increases the work of breathing. Efforts have focused on the potential role of sildenafil in improving exercise performance in high altitude environment. The purpose of this study was to determine the effects of acetazolamide and sildenafil on oxygen uptake (VO 2 ) and breathing efficiency during submaximal hypoxic exercise. Sixteen volunteers received sildenafil 40 mg (S), acetazolamide 125 mg (A) or matching placebo (P) tid × four doses in double‐blind fashion starting 8 hours prior to hypoxic exposure over 3 separate overnight stays in an altitude tent with an O 2 concentration of 12.5%, and then performed hypoxic submaximal exercise on a stationary bicycle for 10 min at a workload of 40% of VO 2 peak. SaO 2 decreased with exercise but there was no difference in exercising SaO 2 or VO 2 between conditions. As expected, acetazolamide increased ventilation compared to placebo and sildenafil. Breathing efficiency as measured by Ve/VCO 2 decreased with acetazolamide in comparison to placebo and sildenafil (P: 42.6±1.2, S: 41.9±1.6, A: 46.7±1.1, p<0.01). Sildenafil did not change breathing efficiency while acetazolamide reduced breathing efficiency during hypoxic exercise. This study was funded by Mayo Foundation and NIH Grant No. HL71478.
Exercise pulmonary gas exchange differentiates type and severity of pulmonary hypertension in heart failure
Smetana, Michael Robert, O’Malley, Kathy A., Johnson, Bruce D. , Taylor, Bryan J. , Frantz, Robert P.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.1182.6 Get It

Background Heart failure (HF) is associated with impaired exercise pulmonary gas exchange (PGX) that is likely related to the development and severity of pulmonary hypertension (PH). Purpose To determine whether PGX measures differentiate HF patients with reactive PH from patients with passive PH or no PH. Methods/Results Pulmonary arterial pressure (P AP ), pulmonary wedge pressure (P WP ), transpulmonary pressure gradient (TPG) and PGX indices [end‐tidal CO 2 (P ET CO 2 ), ventilatory efficiency (V E /VCO 2 ), O 2 pulse, estimated pulmonary arterial capacitance (GX CAP )] were assessed simultaneously at rest and during cycle exercise in 38 HF patients undergoing right heart catheterization. Post hemodynamic evaluation, patients were classified as having no PH ( n = 12), passive PH ( n = 10) or reactive PH ( n = 16). TPG increased during exercise in all groups but was greater at end exercise in the reactive PH vs. the passive PH and no PH patients (21±9 vs. 14±7 vs. 12±7 mmHg). At an equivalent VO 2 , P ET CO 2 , O 2 pulse and GX CAP were higher and V E /VCO 2 ratio lower in the no PH and, to a lesser extent, in the passive PH vs. the reactive PH subjects (Figure 1). Conclusion Noninvasive measures of PGX during exercise appear to differentiate HF patients with reactive PH from patients with passive PH or no PH and may be a useful adjunct to invasive catheterization in assessing PH type and severity. HL71478, AHA12POST12070084, Gilead Science
Breathing Efficiency in Systolic Heart Failure: Impact of Hyperventilation and Dead Space
Woods, Paul R., Olson, Thomas P. , O’Malley, Kathy A., Hulsebus, Minelle L., Johnson, Bruce D. , Frantz, Robert P.

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.615.1 Get It

Background Patients with heart failure (HF) often develop pulmonary system abnormalities. Specifically, an abnormal ventilation relative to metabolic demand (V E /VCO 2 , ventilatory efficiency) during exercise has been shown to be an important marker of disease severity and prognosis. The purpose of this investigation was to focus on the factors that underlie the abnormal breathing efficiency in this population. Methods 14 controls (10 male) and 40 (36 male) mod‐severe HF patients, age 52±12 and 56±8 yrs, respectively, performed graded exercise on a cycle ergometer. Gas exchange and blood gas measurements were made during submaximal exercise (~65% peak VO 2 ) and used to quantify the influence of hyperventilation (PaCO 2 ) and dead space ventilation (V D ) on V E /VCO 2 . Results The V E /VCO 2 ratio was lower in controls (30±4) than in HF (45±9, p<0.001) due to a lower PaCO 2 and higher V D /V T that contributed an estimated 29% and 71%, respectively, to the increased V E /VCO 2 (p<0.05). The elevated V D /V T in HF was in turn the result of a tachypneic breathing pattern (lower V T , 877±306 vs 2003±504ml, p<0.01) in the presence of a relatively normal V D (9.6±3.8 vs 11.9±5.7 L/min, p=0.094). Conclusion The abnormal ventilation in relation to metabolic demand in HF during exercise is predominantly due to alterations in breathing pattern, rather than hyperventilation or changes in ventilation/perfusion relationships. HL71478